Results 11 to 20 of about 1,483,959 (183)

Generalized Chorea and JAK2V617F Mutation-Positive Myeloproliferative Disorders. [PDF]

open access: yesMov Disord Clin Pract, 2020
An 86-year-old right-handed man presented with 1 month of involuntary movements. He had involuntary facial grimacing, tongue chewing, grunting, slurred speech, shoulder shrugging, and leg movements. He was not able to suppress the movements, felt no urge
Betté S, Moore H.
europepmc   +5 more sources

JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis. [PDF]

open access: yesIndian J Hematol Blood Transfus, 2020
Splanchnic vein thrombosis is an uncommon life-threatening form of venous thrombosis. It is one the common complication among MPN's. In the western studies the prevalence of JAK2V617F mutation among SVT patient is high and ranges from 7 to 59%. The frequency of this mutation among Indian SVT patients is heterogenous. This was a prospective case control
Kumar N   +8 more
europepmc   +5 more sources

Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis. [PDF]

open access: yesBlood Adv
Key Points • JAK2V617F mutation contributes to hemorrhagic lesions and to mortality in an experimental model of cerebral venous thrombosis.• JAK2V617F mutation exacerbates thromboinflammatory response during cerebral venous thrombosis.
Bourrienne MC   +21 more
europepmc   +2 more sources

Interleukin-1β, JAK2V617F mutation and inflammation in MPNs. [PDF]

open access: yesBlood Adv
Long before the discovery of the ...
Hermouet S, Hasselbalch HC.
europepmc   +2 more sources

The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden [PDF]

open access: yeseJHaem, 2023
Alleviating symptom burden in patients with myeloproliferative neoplasms (MPNs) is imperative to achieving optimal management. Research remains to elucidate the relationship between the JAK2V617F (Janus kinase 2) mutation present in many MPN patients ...
Lai Yee Orbell   +7 more
doaj   +2 more sources

JAK2V617F Mutation in Ischemic Stroke: Bridging Hematology and Stroke Neurology [PDF]

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Recent evidence suggests the JAK2V617F mutation may confer an elevated risk of ischemic stroke, likely mediated by systemic inflammation, abnormal cell activation, and endothelial dysfunction.
Marie H. Kristiansen   +7 more
doaj   +2 more sources

Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. [PDF]

open access: yesJ Thromb Haemost, 2020
Rational The myeloproliferative neoplasms (MPNs) are clonal hematological malignancies characterized by hematopoietic stem cell expansion and overproduction of mature blood cells.
Castiglione M   +9 more
europepmc   +2 more sources

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm

open access: yesBlood Cancer Journal, 2023
SRSF2 mutations are found in association with JAK2V617F in myeloproliferative neoplasms (MPN), most frequently in myelofibrosis (MF). However, the contribution of SRSF2 mutation in JAK2V617F-driven MPN remains elusive.
Yue Yang   +4 more
doaj   +2 more sources

Thromboinflammation in ischemic cerebrovascular patients with the JAK2V617F mutation. [PDF]

open access: yesThrombosis Research
BACKGROUND The JAK2V617F mutation is a driver of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) and is also implicated in cardiovascular diseases.
M. H. Kristiansen   +9 more
semanticscholar   +4 more sources

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms

open access: yesIndian Journal of Pathology and Microbiology, 2018
Background: It is still a matter of debate regarding the association of JAK2V617F mutation with thrombosis in BCR-ABL negative CMPN patients. The role of JAK2V617F mutation in increasing the thrombotic risk in CMPNs is yet unequivocal.
Kanwaljeet Singh   +4 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy